Skye Bioscience, Inc.
SKYE Healthcare Biotechnology
In the quarter to June 2026, EPS grew 38.6% and free cash flow grew 34.8%, each against the same quarter a year earlier.
Follow SKYE
Skye Bioscience, Inc. (SKYE) EV/Sales
As of 16 October 2026, Skye Bioscience, Inc. (SKYE) trades at a EV/Sales of 12.9×. Over the past ten years it has ranged from −18.1× (April 2025) to 2,139× (January 2015); the current reading is higher than 2% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AIM AIM ImmunoTech Inc. compare | −69.6× |
| SYBX Synlogic, Inc. compare | −0.2× |
| BCLI Brainstorm Cell Therapeutics Inc. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| CALC CalciMedica Inc. compare | n/m |
| XCUR Exicure, Inc. compare | 0.2× |
| NIKI Niki BioSolutions, Inc. compare | 1.3× |
| SKYE Skye Bioscience, Inc. | 12.9× |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | 24.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)